Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of tropomyosin inhibitor in children with neuroblastoma in Australia.

Trial Profile

Clinical trial of tropomyosin inhibitor in children with neuroblastoma in Australia.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tropomyosin inhibitors (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
    • 20 May 2014 This trial is expected to start in 2015, according to a Novogen media release.
    • 20 May 2014 New trial record
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top